Impact of FGFR2/3 activating genomic alterations on response to enfortumab vedotin in metastatic urothelial carcinoma (mUC).

被引：4
|
作者：
Adib, Elio [1 ]
Jain, Rohit K. [2 ]
Skelton, William Paul [3 ]
Freeman, Dory [1 ]
Curran, Catherine [1 ]
Akl, Elie W. [4 ]
Nassar, Amin [4 ]
Ravi, Praful [1 ]
Mantia, Charlene [1 ]
Merchan, Jaime R. [5 ]
Tan, Winston [6 ]
Plastini, Trisha M. [7 ]
Choueiri, Toni K. [1 ,8 ]
Sonpavde, Guru [9 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Lee Moffitt Canc Ctr, Tampa, FL USA
[3] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[4] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA
[5] Univ Miami, Miami, FL USA
[6] Mayo Clin Hosp, Jacksonville, FL USA
[7] Univ Penn Hlth Syst, Philadelphia, PA USA
[8] Harvard Med Sch, Boston, MA 02115 USA
[9] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 06期
关键词：
D O I：
10.1200/JCO.2021.39.6_suppl.472
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
472
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Real-world evidence for enfortumab vedotin (EV) in metastatic urothelial carcinoma (mUC): a multi-centred observational study in a publicly funded Canadian system.
    Peng, Jenny
    Hueniken, Katrina
    Proulx-Rocray, Francis
    Alimohamed, Nimira S.
    Fallah-rad, Nazanin
    Kumar, Vikaash
    Al-Ezzi, Esmail M.
    Jiang, Di
    Blais, Normand
    Sridhar, Srikala S.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [42] Enfortumab vedotin (EV) in patients (Pts) with metastatic urothelial carcinoma (mUC) with prior checkpoint inhibitor (CPI) failure: A prospective cohort of an ongoing phase 1 study.
    Petrylak, Daniel Peter
    Smith, David C.
    Flaig, Thomas W.
    Zhang, Jingsong
    Sridhar, Srikala S.
    Ruether, Joseph D.
    Plimack, Elizabeth R.
    Merchan, Jaime R.
    Quinn, David I.
    Kilari, Deepak
    Srinivas, Sandy
    Baranda, Joaquina Celebre
    Lang, Joshua Michael
    Milowsky, Matthew I.
    Galsky, Matt D.
    Spira, Alexander I.
    Gartner, Elaina M.
    Wu, Chunzhang
    Melhem-Bertrandt, Amal
    Rosenberg, Jonathan E.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [43] Association of body mass index and tumor response in metastatic urothelial carcinoma treated with enfortumab vedotin: data from the ULTRA-Japan consortium
    Uchimoto, Taizo
    Iwatsuki, Kengo
    Komura, Kazumasa
    Fukuokaya, Wataru
    Adachi, Takahiro
    Hirasawa, Yosuke
    Hashimoto, Takeshi
    Yoshizawa, Atsuhiko
    Saruta, Masanobu
    Hashimoto, Mamoru
    Minami, Takafumi
    Yamamoto, Yutaka
    Yamazaki, Shogo
    Takai, Tomoaki
    Sakamoto, Moritoshi
    Nakajima, Yuki
    Nishimura, Kazuki
    Maenosono, Ryoichi
    Tsujino, Takuya
    Nakamura, Ko
    Fukushima, Tatsuo
    Nishio, Kyosuke
    Yoshikawa, Yuki
    Yamamoto, Shutaro
    Iwatani, Kosuke
    Urabe, Fumihiko
    Mori, Keiichiro
    Yanagisawa, Takafumi
    Tsuduki, Shunsuke
    Takahara, Kiyoshi
    Fujita, Kazutoshi
    Kimura, Takahiro
    Ohno, Yoshio
    Shiroki, Ryoichi
    Azuma, Haruhito
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2025, : 761 - 769
  • [44] Sequencing of erdafitinib (erda) and enfortumab vedotin (EV) in patients (pts) with fibroblast growth factor receptor (FGFR2/3) altered (alt) advanced urothelial cancer (aUC): Analysis of UNITE database
    Jiang, Cindy Y.
    Hwang, Hyunsoo
    Jindal, Tanya
    Qiao, Wei
    Epstein, Ilana
    Nguyen, Charles B.
    Gupta, Shilpa
    Shah, Sumit
    Bilen, Mehmet Asim
    Milowsky, Matthew I.
    Hoimes, Christopher J.
    Kilari, Deepak
    Zakharia, Yousef
    Emamekhoo, Hamid
    Grivas, Petros
    Bellmunt, Joaquim
    Alva, Ajjai Shivaram
    Koshkin, Vadim S.
    Campbell, Matthew T.
    Alhalabi, Omar
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL)
  • [45] Population Pharmacokinetic Modeling and Exposure-Response Analysis for the Antibody-Drug Conjugate Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Carcinoma
    Zuo, Peiying
    Bonate, Peter
    Garg, Amit
    Matsangou, Maria
    Tang, Mei
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 116 (05) : 1278 - 1288
  • [46] Are fibroblast growth factor receptor 3 (FGFR3) alterations a possible predictive factor for platinum-based chemotherapy and immunotherapy in metastatic urothelial carcinoma (MUC)?
    Ferrer-Mileo, L.
    Rodriguez Hernandez, A.
    Aversa, C.
    Rodriguez-Carunchio, L.
    Ribera, I.
    Trias Puigsureda, I.
    Oliva, L.
    Jimenez Blasco, N.
    Garcia-Esteve, S.
    Alvarez, M.
    Rabella, M.
    Mellado Gonzalez, B.
    Reig Torras, O.
    ANNALS OF ONCOLOGY, 2023, 34 : S1220 - S1221
  • [47] Pemigatinib for metastatic or surgically unresectable urothelial carcinoma with FGF/FGFR genomic alterations: final results from FIGHT-201
    Necchi, A.
    Pouessel, D.
    Leibowitz, R.
    Gupta, S.
    Flechon, A.
    Garcia-Donas, J.
    Bilen, M. A.
    Debruyne, P. R.
    Milowsky, M. I.
    Friedlander, T.
    Maio, M.
    Gilmartin, A.
    Li, X.
    Veronese, M. L.
    Loriot, Y.
    ANNALS OF ONCOLOGY, 2024, 35 (02) : 200 - 210
  • [48] Recurrent urothelial carcinoma-like FGFR3 genomic alterations in malignant Brenner tumors of the ovary
    Lin, Douglas I.
    Killian, Jonathan K.
    Venstrom, Jeffrey M.
    Ramkissoon, Shakti H.
    Ross, Jeffrey S.
    Elvin, Julia A.
    MODERN PATHOLOGY, 2021, 34 (05) : 983 - 993
  • [49] Impact of Skin Adverse Events on Prognosis in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Treated With Enfortumab Vedotin: A Real-World Multicenter Study
    Ozaki, Kai
    Yamamoto, Hayato
    Sekine, Yuya
    Horiguchi, Hirotaka
    Hosogoe, Shogo
    Mikami, Jotaro
    Fujita, Naoki
    Tokui, Noriko
    Okita, Kazutaka
    Okamoto, Teppei
    Mori, Kanami
    Kobayashi, Mizuki
    Numakura, Kazuyuki
    Yoneyama, Takahiro
    Tabata, Ryuji
    Sato, Satoshi
    Habuchi, Tomonori
    Ohyama, Chikara
    Hatakeyama, Shingo
    INTERNATIONAL JOURNAL OF UROLOGY, 2025,
  • [50] Exceptional Response to Pazopanib in a Patient with Urothelial Carcinoma Harboring FGFR3 Activating Mutation and Amplification
    Palma, Norma
    Morris, John C.
    Ali, Siraj M.
    Ross, Jeffrey S.
    Pal, Sumanta Kumar
    EUROPEAN UROLOGY, 2015, 68 (01) : 168 - 170
12345